Company Description
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany.
The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.
Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients.
The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists.
The company was incorporated in 2007 and is based in Redwood City, California.
Country | United States |
Founded | 2007 |
IPO Date | Jan 30, 2015 |
Industry | Medical Instruments & Supplies |
Sector | Healthcare |
Employees | 68 |
CEO | Jeffrey M. Soinski |
Contact Details
Address: 400 Chesapeake Drive Redwood City, California 94063 United States | |
Phone | 650-363-2400 |
Website | avinger.com |
Stock Details
Ticker Symbol | AVGR |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001506928 |
CUSIP Number | 053734604 |
ISIN Number | US0537348775 |
Employer ID | 20-8873453 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Jeffrey M. Soinski | President, Chief Executive Officer and Director |
Nabeel P. Subainati | Vice President of Finance, Principal Financial Officer and Accounting Officer |
Himanshu N. Patel | Chief Technology Officer |
Keith Schaefer | Chief Operating Officer |
Philip R. Preuss | Chief Marketing Officer and Vice President of Business Operations |
Corey Gibbs | Vice President of Sales |
Dr. Jaafer Golzar FACC, M.D. | Chief Medical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 28, 2024 | PRE 14A | Other preliminary proxy statements |
Jun 21, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Jun 18, 2024 | 8-K | Current Report |
Jun 17, 2024 | 424B4 | Prospectus |
Jun 13, 2024 | EFFECT | Notice of Effectiveness |
Jun 12, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
Jun 10, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
Jun 7, 2024 | 8-K | Current Report |
Jun 3, 2024 | SCHEDULE 13D/A | Filing |
May 31, 2024 | SD | Form - SD |